Supplementary Figure 2 from Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors

Abstract

<p>Changes in peripheral GITR+ effector memory T-cells from baseline were measured in the 25 mg, 75 mg, 250 mg, and 500 mg cohorts.</p>